Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
PHASE3
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that bi...
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
PHASE3
Primary Objective:
To provide participants with severe hypercholesterolemi...
Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO]
PHASE4
This study aim is to evaluate the additional effect of eicosapentaenoic aci...
Status
Unknown
Location
Kobe University Graduate School of Medicine, Department of Cardiology
Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention
PHASE4
\[Purpose of the Clinical Study\]:The purpose of this study is to conduct a...